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Ex vivo evaluation of the mucoadhesive
properties of Cedrela odorata and Khaya
senegalensis gums with possible applications
for veterinary vaccine delivery
B. Emikpe, V.O. Oyebanji ∗, T. Jarikre, D. Odeniyi,
A. Salami, O. Oladele, O. Akinboade
University of Ibadan„ Ibadan, Nigeria
Background: The use of mucoadhesives in drug vehicle design
has gained considerable attention over the past decades however,
studies designed to evaluate the interaction of bioadhesives with
biologic tissues with a view of application for non-invasive vac-
cine delivery in veterinary subjects’ is scanty in literature. Hence,
this study evaluates the peak adhesion time as well as capacity for
vaccine delivery through the mucosal route of some phytogenic
mucoadhesive polymers.
Methods&Materials: Gumgels fromCedrela odorata andKhaya
senegalensis were harvested, puriﬁed, lyophilized and compressed
into 500mg tablets individually and in combined ratios of 1:1, 1:3
respectively. These tablets were placed on freshly excised (about
5x5cm) trachea and duodenal tissues of cattle, chicken, pig, sheep
and goat which were fastened to the basket end of a tablet dis-
solution machine probe. The probe set at 50rev/min was lowered
into phosphate buffer at 6.8 pH in a beaker immersed inwater bath
at 37OC. The time it takes for the gum tablet to fall off the tissue
under this condition is recorded as the peak adhesion time (PAT)
of the gum polymer. The gum polymer with the best PAT was com-
bined with Newcastle disease vaccine and the procedure repeated.
Haemagglutinationassay (HA)wasconductedon thegumpolymer-
vaccine mix with gum and vaccine individually as controls.
Results: On cattle, chicken and sheep tissues, Cedrela-Khaya
(1:1) mix had the highest PAT; goat, Cedrela-Khaya (1:3) mix
while either Cedrela-Khaya (1:1) mix or Cedrela alone was best
for pig tissues. On combination with vaccine, the PAT of the gums
reduced slightly on cattle and sheep tissues while other animal tis-
sue showedvaried results. TheHA results showed the gumpolymer
boosted the HA property of the vaccine (Log105), when compared
to vaccine alone (Log 104). There was presence of HA property in
the gum polymer alone. With a checkerboard dilution, the mini-
mum dilution with the least HA property was recommended for
vaccine dilution and in vivo application.
Conclusion: In conclusion, mucoadhesives from phytogenic
sources has potentials for non-invasive vaccine application with
possible ampliﬁcation of duration of immune vaccine response.
http://dx.doi.org/10.1016/j.ijid.2016.02.902
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Identiﬁcation and characterization of a novel
protein PfCDPK-5 for the development of
pediatric malaria vaccine
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1 Brown University, Providence, Rhode Island, USA
2 Centre for International Health Research,
Providence, USA
3 Brown University, Providence, USA
Background: Malaria are among the leading causes of mortal-
ity for children under ﬁve years of age worldwide, with most of
these deaths resulting from Plasmodium falciparum infection. Resis-
tance to existing anti-malarial medications is an urgent problem
and may prevent effective eradication strategies. Despite decades
of research, no vaccine candidate has been shown to confer sig-
niﬁcant protection to children. Though marginal protection has
been achieved using the vaccine candidate RTS, S/AS01 and irradi-
ated sporozoites, broadly effective vaccine candidates are urgently
needed. The immediate goals of this study are to gain an immuno-
logical understanding of anti-PfCDPK-5 antibodies in preventing
parasite maturation and egress.
Methods &Materials: In ongoing antigen discovery studies, we
pioneered a high-throughput differential whole proteome screen-
ing method (phase display) to identify parasite epitopes associated
with resistance to malaria in children. We utilized this approach
to identify targets of antibodies that protect children from severe
malaria ormalaria-speciﬁcmortality and identiﬁed Schizont Egress
Antigen-1 (Raj et. al Science 2014). In a parallel screening experi-
ment, we used sera from11 resistant and 14 susceptible children to
differentially screen a parasite phage display cDNA library gener-
ated from parasite collected from African children. The localization
study andgrowth inhibition activitywere evaluated as per our pub-
lishedmethods. Anti-rPfCDPK-5antibody levels in theentire cohort
measured by a bead-based assay.
Descriptive characteristics of Resistant and Susceptible chil-
dren
Enrichment of antigens binding to malaria resistant kids
antibodies
Results:We identiﬁedantibodies against PfCDPK-5protein only
in malaria resistant kids sera, not in susceptible kids sera. The pre-
liminary data show that PfCDPK-5 phosphorylates PfSEA-1 another
important protein responsible for egress of parasites. The poly-
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clonal antibodies generated by recombinant PfCDPK-5 protein or
DNA vaccine shows signiﬁcant growth inhibition activity in in vitro
assays. Anti-rPfCDPK-5 antibody levels in the entire cohort shows
a positive correlation to morbidity and mortality of children.
PfCDPK-5 phosphorylate PfSEA-1
Conclusion: In the present study, we validate a rationally iden-
tiﬁed vaccine candidate, P. falciparum calcium-dependent protein
kinase 5(PfCDPK-5) using integrated translational approaches that
harness high-throughput molecular techniques and in vitro func-
tional assays.
http://dx.doi.org/10.1016/j.ijid.2016.02.903
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Lesson learned from investigating cluster
adverse event following immunization in mass
campaign of Japanese Encephalitis vaccine in
India
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1 Public Health Foundation of India, Delhi, Delhi,
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2 Public Health Foundation of India, Delhi, India
3 MoHFW, New Delhi, India
4 Public Health Foundation of India, New Delhi, India
Background: Vaccine safety is one of the critical parameters
for quality assurance in immunization program in all countries
including developing country like India as it adds new vaccines to
its existing immunization program. Occurrence of adverse events
following immunization (AEFI) and spread of unchecked rumors
can hamper community conﬁdence in vaccines adversely affect-
ing coverage. Cluster AEFI (2 or more reports occurring together)
get heightened attention from media, government and community
and can affect performance of immunization program. In commit-
ment to improve vaccine safety, this paper summarizes a report
of a cluster investigation for AEFIs (90 reports) following Japanese
Encephalitis (JE) vaccine given in a mass campaign in one district
(Morigoan of Assam), India in June, 2014.
Methods & Materials: In response to received reports of AEFI
cluster over 10 day’s period in June 2014, National AEFI surveil-
lance team had investigated the reason for the events in the ﬁeld
by interviewing community and reviewing hospital records. Data
of the individual cases was entered in anonymized line list and
analyzed by using SPSS vs. 16.
Results: In Morigoan, 200574 doses of JE vaccine was adminis-
tered in 1- 15 years age groupduring 15days period in 2014 inmass
campaignandamong these89of the caseshave reported symptoms
of dizziness, tingling and numbness and abnormal movement of
limbs.More than two- thirdof theaffected individualswere females
having median age of 9 years. Cases recovered without any resid-
ual sequel after receiving conservative treatment, reassurance and
counselling in hospital.
Conclusion: There is a need of multi-pronged, effective infor-
mation, education and communication intervention to handle
unwanted rumors to ensure vaccine conﬁdence during mass cam-
paign by involving multiple stake holders.
http://dx.doi.org/10.1016/j.ijid.2016.02.904
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The seroprevalence of neutralizing antibody
against Japanese encephalitis virus in health
care workers
W.P. Vandepitte1,∗, S. Yoksan2, M. Wannachart1
1 Queen Sirikit National Institute of Child Health,
Bangkok, Thailand
2 Institute of Molecular Biosciences, Nakhonpathom,
Salaya, Thailand
Background: Despite the introduction of inactivated Japanese
encephalitis (JE) vaccine since 1990, JE remains an important cause
of viral encephalitis in Thailand. Little is known about JE serosta-
tus among Thais who were born before the 2001, the year that this
vaccine has been included in the expanded immunization program.
Therefore, the objective of this study was to determine the propor-
tion of healthcareworkers (HCWs) aged 21-60 yearswith adequate
neutralizing antibody against JE virus.
Methods & Materials: We conducted a seroprevalence survey
among HCWs during the routine annual check-up for HCWs at
Queen Sirikit National Institute of ChildHealth (Children’sHospital,
Bangkok, Thailand)during theperiodbetween July-October2015.A
purposive samplingwas done to enroll a relatively equal number of
4 different age ranges i.e., 21-30, 31-40, 41-50, and 51-60 years per
each group. JE serostatus was determined using 50% Plaque Reduc-
tion Neutralization Test (PRNT). Immunity to JE were quantitated
and cross-tabulated against age, gender, past and present domicile,
history of JE vaccination, types of vaccine received (if any).
Results: A total of 400 HCWs among a total of 1,320 who
received annual check-up were enrolled. Only 1.5% of participants
reported having immunized with JE vaccine. 80.5% demonstrated
an adequate existing antibody against JE virus genotype 3 Beijing
strain (at least 10 reciprocal PRNT titer). The proportion of protec-
tive antibody (and corresponding geometric mean titer) of the 4
age groups were 77.0% (112.48), 82.4% (211.47), 80.6% (84.59), and
82.0%(126.97) among those aged 21-30, 31-40, 41-50, and 51-60,
respectively.Male genderwas the only parameter that signiﬁcantly
associatedwith the lack of protective JE antibodywith risk ratio and
95% conﬁdence interval of 1.69 (1.1, 2.7).
Conclusion: Since JE virus is unlikely to be transmitted in hospi-
tal settings, the result from this groupmight be reﬂective of those in
the general adult population in Bangkok. As a result, approximately
